Loading...
01/11 03:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong membership growth, revenue projections, and an optimistic outlook for 2026, with investments in automation and quality improvements. The Q&A section supports these with discussions on favorable SG&A variance, strong retention, and strategic investments, despite some uncertainties in competitive environments. The overall sentiment is positive, driven by strategic growth plans and financial health improvements.
Health Plan Membership 229,600 members, representing growth of approximately 26% year-over-year. Growth driven by strong new member sales.
Total Revenue $994 million, increasing approximately 44% year-over-year. Growth supported by strong health plan membership growth.
Adjusted Gross Profit $127 million, increased by 58% year-over-year. Improvement driven by disciplined execution of clinical activities and lower inpatient admissions per 1,000 in the low 140s.
Consolidated MBR (Medical Benefit Ratio) 87.2%, an improvement of 120 basis points year-over-year. Improvement attributed to disciplined clinical execution and moderated growth in utilization trends.
Adjusted SG&A Ratio 9.6%, improved by 120 basis points year-over-year. Improvement driven by scalability of the operating platform and timing benefits in SG&A expenses.
Adjusted EBITDA $32 million, representing 240 basis points of margin expansion compared to the third quarter of 2024. Improvement driven by strong execution and scalability of operations.
Cash, Cash Equivalents, and Investments $644 million at the end of the third quarter. Increase due to timing of certain medical expense payments, which resulted in higher operating cash flow during the quarter.
Health plan membership: 229,600 members, representing a 26% year-over-year growth.
Revenue: $994 million, a 44% year-over-year increase.
Adjusted gross profit: $127 million, a 58% year-over-year increase.
Adjusted EBITDA: $32 million, surpassing guidance.
Geographic expansion: Strong performance in California, North Carolina, Nevada, and Texas. California HMO contract earned a 4-star rating for the ninth consecutive year. Two 5-star contracts in North Carolina and Nevada, and 4.5 stars in Texas in its first rating year.
Market share: Expected 20% year-over-year growth in membership for 2026, with a focus on markets with strong provider relationships.
Operational improvements: Investments in back-office automation, clinical engagement, AVA AI clinical stratification, and Stars durability.
Cost management: Adjusted SG&A ratio improved to 9.6%, a 120 basis points improvement year-over-year.
Strategic focus: Balancing membership growth and profitability objectives, leveraging care management capabilities to maintain stable benefits.
CMS transition: Adapting to CMS' new health outcomes reward system, focusing on clinical outcomes for vulnerable low-income seniors.
Regulatory Changes: The transition to the excellent health outcomes for all reward (formerly Health Equity Index) by CMS introduces new criteria for health plans, which could pose challenges in maintaining high star ratings and associated funding advantages.
Medicare Advantage Industry Disruption: Continued disruption in the Medicare Advantage (MA) industry in 2026 could create uncertainties and challenges in maintaining growth and profitability.
Seasonal Utilization Impact: Higher medical utilization in the final months of the year, including the seasonal impact of the flu, could increase the MBR and affect profitability.
Part D Program Changes: Significant changes to the Part D program introduce uncertainties in utilization trends and margin assumptions, requiring careful management to meet financial targets.
Growth-Related Costs: Expected increase in SG&A expenses during the fourth quarter due to growth-related costs and timing of certain expenses could impact profitability.
Competitive Pressures: The need to balance membership growth and profitability objectives amidst competitive pressures in the Medicare Advantage market could strain resources and strategic execution.
Adjusted EBITDA for 2025: The company expects to deliver $94 million of adjusted EBITDA at the midpoint of its guidance range for 2025, compared to the initial guidance of $47.5 million.
Stars Ratings and Future Implications: 100% of health plan members are in plans rated 4 stars or above for rating year 2026, payment year 2027. The company expects the improvement in the raw star score of its California HMO plan to set a solid foundation for rating year 2027 and payment year 2028. CMS' transition to the excellent health outcomes for all reward is expected to add cushion to the 4-star rating in California.
2026 Annual Enrollment Period (AEP) and Membership Growth: The company is taking a measured approach to balance membership growth and profitability objectives. It expects to grow at least 20% year-over-year in 2026, supported by early AEP results and a focus on matching seniors with the right products and growing in markets with strong provider relationships.
Revenue and Membership Guidance for 2025: For the full year 2025, revenue is expected to be in the range of $3.93 billion to $3.95 billion, with year-end membership guidance raised by 2,000 members at the midpoint. Fourth-quarter revenue is expected to range between $995 million and $1.01 billion, with health plan membership between 232,500 and 234,500 members.
Adjusted Gross Profit and MBR for 2025: The company updated its adjusted gross profit guidance to $479 million at the midpoint, reflecting an MBR of 87.9% and nearly 100 basis points of improvement year-over-year. Fourth-quarter adjusted gross profit is expected to range between $104 million and $113 million.
2026 Market Opportunities and Industry Disruption: The company anticipates incremental opportunities to gain market share in 2026 due to continued disruption in the Medicare Advantage industry, while also growing adjusted EBITDA year-over-year.
The selected topic was not discussed during the call.
The earnings call reveals strong membership growth, revenue projections, and an optimistic outlook for 2026, with investments in automation and quality improvements. The Q&A section supports these with discussions on favorable SG&A variance, strong retention, and strategic investments, despite some uncertainties in competitive environments. The overall sentiment is positive, driven by strategic growth plans and financial health improvements.
The earnings call summary reflects strong financial performance with significant revenue and profit growth, alongside improved operational efficiency. Market strategy and product development updates are promising, with a focus on technology and market expansion. The Q&A insights reveal stable utilization trends, efficient SG&A management, and positive member engagement, all contributing to a positive outlook. Despite management's reluctance to provide specific marketing details, the overall sentiment is positive due to robust guidance and strategic investments, indicating potential stock price growth of 2% to 8%.
The company demonstrated strong financial performance with significant revenue growth and adjusted EBITDA margin expansion. Despite competitive pressures and some regulatory challenges, the company is less impacted by regulatory changes compared to competitors. The guidance for 2025 is optimistic with raised revenue and adjusted EBITDA outlooks. Analysts showed positive sentiment, particularly about the company's competitive position and financial stability. Although there are risks, the overall sentiment and guidance suggest a positive stock price movement in the short term for this small-cap company.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
